BioSpace News Archive

biote Corp. today announced the Company will provide second quarter financial results on Thursday, August 10, 2023, after the close of the market.

Femasys Inc. announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 16/402,193 further strengthening Femasys’ intellectual property position and coverage for the Company’s therapeutic product candidate, FemBloc® permanent birth control.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year.

Editas Medicine, Inc. and Azzur Cleanrooms on Demand™, an Azzur Group company, announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia, from approval to commercialization.

Celularity Inc. and Verséa Ophthalmics, LLC today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Verséa Ophthalmics will distribute Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.

Eclipsebio, a leading provider of innovative RNA analysis solutions, announces the launch of its proprietary eRibo Pro™ service, an all-inclusive offering to identify differential transcription and translation as well as ribosome positioning

Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced that it has been granted FDA clearance for its AI-powered ultrasound guidance technology.

CNS Pharmaceuticals, Inc. today announced that its abstract has been selected for in-person poster presentation at the 2023 SNO/ASCO CNS Cancer Conference being held August 10-12, 2023 in San Francisco, CA.

ABVC BioPharma, Inc. today announced it has entered into a definitive securities purchase agreement with a single institutional investor to purchase $1.75 million worth of its common stock in a registered direct offering (the “Offering”).

AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its Q2 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive resource on new, pending and projected Specialty and Rare Disease drug launches, and cell and gene therapies, biosimilars and generics.